{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:47:43Z","timestamp":1783435663495,"version":"3.54.6"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bayer AG and Merck Sharp & Dohme LLC"},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nippon Shinyaku Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To examine disease and target engagement biomarkers in the RISE-SSc trial of riociguat in early diffuse cutaneous systemic sclerosis and their potential to predict the response to treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients were randomized to riociguat (n\u2009=\u200960) or placebo (n\u2009=\u200961) for 52\u2009weeks. Skin biopsies and plasma\/serum samples were obtained at baseline and week 14. Plasma cyclic guanosine monophosphate (cGMP) was assessed using radio-immunoassay. \u03b1-Smooth muscle actin (\u03b1SMA) and skin thickness were determined by immunohistochemistry, mRNA markers of fibrosis by qRT-PCR in skin biopsies, and serum CXC motif chemokine ligand 4 (CXCL-4) and soluble platelet endothelial cell adhesion molecule-1 (sPECAM-1) by enzyme-linked immunosorbent assay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>By week 14, cGMP increased by 94\u2009(78)% with riociguat and 10\u2009(39)% with placebo (P\u2009&amp;lt;\u20090.001, riociguat vs placebo). Serum sPECAM-1 and CXCL-4 decreased with riociguat vs placebo (P\u2009=\u20090.004 and P\u2009=\u20090.008, respectively). There were no differences in skin collagen markers between the two groups. Higher baseline serum sPECAM-1 or the detection of \u03b1SMA-positive cells in baseline skin biopsies was associated with a larger reduction of modified Rodnan skin score from baseline at week 52 with riociguat vs placebo (interaction P-values 0.004 and 0.02, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Plasma cGMP increased with riociguat, suggesting engagement with the nitric oxide\u2013soluble guanylate cyclase\u2013cGMP pathway. Riociguat was associated with a significant reduction in sPECAM-1 (an angiogenic biomarker) vs placebo. Elevated sPECAM-1 and the presence of \u03b1SMA-positive skin cells may help to identify patients who could benefit from riociguat in terms of skin fibrosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>Clinicaltrials.gov, NCT02283762.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae150","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T22:45:46Z","timestamp":1709937946000},"page":"3124-3134","source":"Crossref","is-referenced-by-count":4,"title":["Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-4453","authenticated-orcid":false,"given":"Dinesh","family":"Khanna","sequence":"first","affiliation":[{"name":"Division of Rheumatology, University of Michigan , Ann Arbor, MI,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kramer","sequence":"additional","affiliation":[{"name":"Research and Development, Pharmaceuticals, Bayer AG , Wuppertal,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"H\u00f6fler","sequence":"additional","affiliation":[{"name":"Staburo GmbH , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedeh","family":"Ghadessi","sequence":"additional","affiliation":[{"name":"Research and Development, Pharmaceuticals, Bayer AG , Wuppertal,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sandner","sequence":"additional","affiliation":[{"name":"Research and Development, Pharmaceuticals, Bayer AG , Wuppertal,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[{"name":"Rheumatology A Department, Cochin Hospital, APAP, Paris Descartes University , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8938","authenticated-orcid":false,"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[{"name":"Division of Medicine, Centre for Rheumatology, University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Firenze , Florence,","place":["Italy"]},{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet E","family":"Pope","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Schulich School of Medicine, University of Western Ontario , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radim","family":"Be\u010dv\u00e1\u0159","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University , Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Czirj\u00e1k","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Medical School, University of P\u00e9cs , P\u00e9cs,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-2146","authenticated-orcid":false,"given":"Ellen","family":"De Langhe","sequence":"additional","affiliation":[{"name":"Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Division of Rheumatology, Department of Development and Regeneration, KU Leuven, University Hospitals Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, Referral Centre for Centre for Rare Systemic Autoimmune Diseases North and North-West of France, CHU Lille, University of Lille, Inserm, U1286 - INFINITE\u2014Institute for Translational Research in Inflammation , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[{"name":"Clinical Research, Innovation and Education Center, Tohoku University , Sendai,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Gunma University Postgraduate School of Medicine , Maebashi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu R","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Toronto Western Hospital, University Health Network, Mount Sinai Hospital, University of Toronto, Toronto Scleroderma Research Program , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Riccieri","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Schiopu","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Medical College of Georgia at Augusta University , Augusta, GA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M","family":"Silver","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Immunology, Medical University of South Carolina , Charleston, SC,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-7945","authenticated-orcid":false,"given":"Vanessa","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ghent University, Belgium and Department of Rheumatology, Ghent University Hospital, Belgium, and Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center , Ghent,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Stagnaro","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa , Pisa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Steen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Georgetown University Medical Center , Washington, DC,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, St Vincent's Hospital Melbourne , Melbourne, VIC,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Sz\u00fccs","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen , Debrecen,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Elise","family":"Truchetet","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, CHU Bordeaux , Bordeaux,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Wosnitza","sequence":"additional","affiliation":[{"name":"Research and Development, Pharmaceuticals, Bayer AG , Wuppertal,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-8310","authenticated-orcid":false,"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Zurich, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,9]]},"reference":[{"key":"2024110419221581300_keae150-B1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"2024110419221581300_keae150-B2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2024110419221581300_keae150-B3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2024110419221581300_keae150-B4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic sclerosis-associated interstitial lung disease: how to incorporate two Food and Drug Administration-approved therapies in clinical practice","volume":"74","author":"Khanna","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024110419221581300_keae150-B5","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/annrheumdis-2014-206809","article-title":"Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies","volume":"74","author":"Dees","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024110419221581300_keae150-B6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/164_2019_249","article-title":"Soluble guanylate cyclase stimulators and activators","volume":"264","author":"Sandner","year":"2021","journal-title":"Handb Exp Pharmacol"},{"key":"2024110419221581300_keae150-B7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","article-title":"Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence","volume":"122(Suppl 1)","author":"Sandner","year":"2017","journal-title":"Respir Med"},{"key":"2024110419221581300_keae150-B8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"2024110419221581300_keae150-B9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(16)30019-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial","volume":"4","author":"Ghofrani","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024110419221581300_keae150-B10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","article-title":"Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2","volume":"76","author":"Humbert","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024110419221581300_keae150-B11","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s40261-018-0698-1","article-title":"Riociguat for the treatment of raynaud's phenomenon: a single-dose, double-blind, randomized, placebo-controlled cross-over pilot study (DIGIT)","volume":"38","author":"Huntgeburth","year":"2018","journal-title":"Clin Drug Investig"},{"key":"2024110419221581300_keae150-B12","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024110419221581300_keae150-B13","author":"FDA-NIH Biomarker Working Group, Silver Spring (MD), Food and Drug Administration (US), Bethesda (MD), (US) NIoH","year":"2016"},{"key":"2024110419221581300_keae150-B14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2017-211912","article-title":"Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study","volume":"77","author":"Herrick","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024110419221581300_keae150-B15","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1136\/annrheumdis-2015-208024","article-title":"Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis","volume":"75","author":"Dobrota","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024110419221581300_keae150-B16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","article-title":"Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database","volume":"74","author":"Maurer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024110419221581300_keae150-B17","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2024110419221581300_keae150-B18","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"2024110419221581300_keae150-B19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/toxins9030092","article-title":"Toxic dimethylarginines: asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA)","volume":"9","author":"Tain","year":"2017","journal-title":"Toxins (Basel"},{"key":"2024110419221581300_keae150-B20","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/rheumatology\/kei276","article-title":"Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine","volume":"45","author":"Dooley","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419221581300_keae150-B21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1755-1536-3-25","article-title":"Autocrine transforming growth factor beta signaling regulates extracellular signal-regulated kinase 1\/2 phosphorylation via modulation of protein phosphatase 2A expression in scleroderma fibroblasts","volume":"3","author":"Samuel","year":"2010","journal-title":"Fibrogenesis Tissue Repair"},{"key":"2024110419221581300_keae150-B22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/art.23146","article-title":"Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts","volume":"58","author":"Chen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2024110419221581300_keae150-B23","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00005344-200003000-00007","article-title":"The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rat platelets","volume":"35","author":"Becker","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"2024110419221581300_keae150-B24","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.3390\/jcm9113388","article-title":"Potential biomarkers in systemic sclerosis: a literature review and update","volume":"9","author":"Utsunomiya","year":"2020","journal-title":"J Clin Med"},{"key":"2024110419221581300_keae150-B25","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.5152\/eurjrheum.2020.19065","article-title":"Biomarkers as an opportunity to stratify for outcome in systemic sclerosis","volume":"7","author":"Abignano","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"2024110419221581300_keae150-B26","first-page":"2460","article-title":"Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc","volume":"28","author":"Sato","year":"2001","journal-title":"J Rheumatol"},{"key":"2024110419221581300_keae150-B27","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1161\/ATVBAHA.107.151456","article-title":"PECAM-1: a multi-functional molecule in inflammation and vascular biology","volume":"27","author":"Woodfin","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024110419221581300_keae150-B28","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3389\/fimmu.2018.02452","article-title":"Unraveling SSc pathophysiology; the myofibroblast","volume":"9","author":"van Caam","year":"2018","journal-title":"Front Immunol"},{"key":"2024110419221581300_keae150-B29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1755-1536-4-9","article-title":"Thrombospondin 1 is a key mediator of transforming growth factor beta-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)\/extracellular signal-regulated kinase (ERK)-dependent mechanism","volume":"4","author":"Chen","year":"2011","journal-title":"Fibrogenesis Tissue Repair"},{"key":"2024110419221581300_keae150-B30","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.ajpath.2012.02.004","article-title":"Recent developments in myofibroblast biology: paradigms for connective tissue remodeling","volume":"180","author":"Hinz","year":"2012","journal-title":"Am J Pathol"},{"key":"2024110419221581300_keae150-B31","doi-asserted-by":"crossref","first-page":"R1113","DOI":"10.1186\/ar1790","article-title":"Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis","volume":"7","author":"Rajkumar","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"2024110419221581300_keae150-B32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/ard.2007.086850","article-title":"Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta","volume":"68","author":"Farina","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2024110419221581300_keae150-B33","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1002\/art.22186","article-title":"Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis","volume":"54","author":"Kissin","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2024110419221581300_keae150-B34","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest"},{"key":"2024110419221581300_keae150-B35","doi-asserted-by":"crossref","first-page":"521958","DOI":"10.1155\/2012\/521958","article-title":"Modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants","volume":"2012","author":"Dooley","year":"2012","journal-title":"Cardiol Res Pract"},{"key":"2024110419221581300_keae150-B36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/cei.13599","article-title":"Endothelial-to-mesenchymal transition in systemic sclerosis","volume":"205","author":"Di Benedetto","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"2024110419221581300_keae150-B37","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1083\/jcb.128.6.1229","article-title":"Mapping the homotypic binding sites in CD31 and the role of CD31 adhesion in the formation of interendothelial cell contacts","volume":"128","author":"Fawcett","year":"1995","journal-title":"J Cell Biol"},{"key":"2024110419221581300_keae150-B38","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3899\/jrheum.150088","article-title":"The endothelial-mesenchymal transition in systemic sclerosis is induced by endothelin-1 and transforming growth factor-beta and may be blocked by macitentan, a dual endothelin-1 receptor antagonist","volume":"42","author":"Cipriani","year":"2015","journal-title":"J Rheumatol"},{"key":"2024110419221581300_keae150-B39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","article-title":"Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis","volume":"37","author":"Hamaguchi","year":"2010","journal-title":"J Dermatol"},{"key":"2024110419221581300_keae150-B40","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"2024110419221581300_keae150-B41","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","article-title":"Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort","volume":"78","author":"Wu","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024110419221581300_keae150-B42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N Engl J Med"},{"key":"2024110419221581300_keae150-B43","doi-asserted-by":"crossref","first-page":"110189","DOI":"10.1016\/j.celrep.2021.110189","article-title":"CXCL4 drives fibrosis by promoting several key cellular and molecular processes","volume":"38","author":"Affandi","year":"2022","journal-title":"Cell Rep"},{"key":"2024110419221581300_keae150-B44","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/acr.21968","article-title":"Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024110419221581300_keae150-B45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024110419221581300_keae150-B46","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1111\/bph.13286","article-title":"The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood","volume":"172","author":"Reiss","year":"2015","journal-title":"Br J Pharmacol"},{"key":"2024110419221581300_keae150-B47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00281-015-0505-5","article-title":"Vasculopathy in scleroderma","volume":"37","author":"Asano","year":"2015","journal-title":"Semin Immunopathol"},{"key":"2024110419221581300_keae150-B48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jdermsci.2021.07.006","article-title":"Contribution to the peripheral vasculopathy and endothelial cell dysfunction by CXCL4 in systemic sclerosis","volume":"104","author":"Jiang","year":"2021","journal-title":"J Dermatol Sci"},{"key":"2024110419221581300_keae150-B49","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2665-9913(23)00238-2","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial","volume":"5","author":"Distler","year":"2023","journal-title":"Lancet Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae150\/57312843\/keae150.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/11\/3124\/60415532\/keae150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/11\/3124\/60415532\/keae150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T19:22:43Z","timestamp":1730748163000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/11\/3124\/7625109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,9]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,3,9]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae150","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,3,9]]}}}